{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:25:20Z","timestamp":1773473120197,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.14283\/jpad.2021.12","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T10:32:23Z","timestamp":1617100343000},"page":"286-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program"],"prefix":"10.1016","volume":"8","author":[{"given":"Tyler","family":"Berkness","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Flournoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.D.","family":"Grill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.14283\/jpad.2021.12_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"18","key":"10.14283\/jpad.2021.12_bib3","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/WNL.0000000000003907","article-title":"Randomized controlled trials in mild cognitive impairment: Sources of variability","volume":"88","author":"Petersen","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.14283\/jpad.2021.12_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jalz.2012.12.001","article-title":"Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future","volume":"9","author":"Geda","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.14283\/jpad.2021.12_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/1567205043332027","article-title":"Regression to the mean: implications for clinical trials of psychotropic agents in dementia","volume":"1","author":"Cummings","year":"2004","journal-title":"Current Alzheimer research"},{"issue":"8","key":"10.14283\/jpad.2021.12_bib6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","article-title":"Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease","volume":"65","author":"Fleisher","year":"2008","journal-title":"Arch Neurol"},{"issue":"4","key":"10.14283\/jpad.2021.12_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet neurology"},{"key":"10.14283\/jpad.2021.12_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial","author":"van Dyck","year":"2019","journal-title":"JAMA neurology"},{"issue":"16","key":"10.14283\/jpad.2021.12_bib9","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000295996.54210.69","article-title":"Disease-modifying therapies for Alzheimer disease: challenges to early intervention","volume":"69","author":"Cummings","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.14283\/jpad.2021.12_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/alzrt58","article-title":"Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials","volume":"2","author":"Grill","year":"2010","journal-title":"Alzheimers Res Ther"},{"issue":"14","key":"10.14283\/jpad.2021.12_bib11","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMsb030172","article-title":"Research involving cognitively impaired adults","volume":"348","author":"Karlawish","year":"2003","journal-title":"The New England journal of medicine"},{"issue":"4","key":"10.14283\/jpad.2021.12_bib12","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2215-0366(17)30089-5","article-title":"Expanding engagement with the ethical implications of changing definitions of Alzheimer's disease","volume":"4","author":"Milne","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.14283\/jpad.2021.12_bib13","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.289.10.1278","article-title":"Central challenges facing the national clinical research enterprise","volume":"289","author":"Sung","year":"2003","journal-title":"JAMA"},{"issue":"1","key":"10.14283\/jpad.2021.12_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MJT.0b013e31815fa75a","article-title":"Racial disparities among clinical research investigators","volume":"15","author":"Getz","year":"2008","journal-title":"Am J Ther"},{"issue":"5","key":"10.14283\/jpad.2021.12_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1037\/0022-006X.64.5.875","article-title":"Issues and recommendations for the recruitment and retention of older ethnic minority adults into clinical research","volume":"64","author":"Arean","year":"1996","journal-title":"Journal of consulting and clinical psychology"},{"issue":"Suppl","key":"10.14283\/jpad.2021.12_bib16","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/WAD.0b013e3181f12869","article-title":"Recruitment and retention of ethnic minority elders into clinical research","volume":"24","author":"Rabinowitz","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"10.14283\/jpad.2021.12_bib17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1377\/hlthaff.2013.1314","article-title":"Obstacles and opportunities in Alzheimer's clinical trial recruitment","volume":"33","author":"Watson","year":"2014","journal-title":"Health affairs (Project Hope)"},{"issue":"Suppl2","key":"10.14283\/jpad.2021.12_bib18","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1097\/00002093-200200002-00009","article-title":"Increasing ethnic minority participation in Alzheimer disease research","volume":"16","author":"Olin","year":"2002","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"10.14283\/jpad.2021.12_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/01.wad.0000190803.11340.66","article-title":"Recruitment strategies for studying dementia in later life among diverse cultural groups","volume":"19","author":"Dilworth-Anderson","year":"2005","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Suppl2","key":"10.14283\/jpad.2021.12_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.18865\/ed.30.S2.705","article-title":"Together We Make the Difference: National Strategy for Recruitment and Participation in Alzheimer's and Related Dementias Clinical Research","volume":"30","author":"Elliot","year":"2020","journal-title":"Ethnicity & disease"},{"key":"10.14283\/jpad.2021.12_bib21","first-page":"7","article-title":"ADRD Summit 2019 Report to the National Advisory Neurological Dosirders and Stroke Counsil","author":"Schneider","year":"2019","journal-title":"Alzheimer's Disease-Related Dementias"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:13:50Z","timestamp":1737339230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724005193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2274580724005193"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2021.12","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2021.12","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}